These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 7191280)
1. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma. Bhargava AS; Heinick J; Schöbel C; Günzel P Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280 [TBL] [Abstract][Full Text] [Related]
2. Characterization of a new potent heparin. 7th communication: A comparative study of a new potent heparin in human after i.v. application. Bhargava AS; Wendt H; Günzel P Arzneimittelforschung; 1981; 31(2):386-8. PubMed ID: 7194658 [TBL] [Abstract][Full Text] [Related]
3. Characterization of a new potent heparin. 3rd Communication: Determinations of anticoagulant activity of a new potent heparin preparation by thrombelastography in vitro using citrated dog and human blood. Bhargava AS; Freihube G; Günzel P Arzneimittelforschung; 1980; 30(8):1256-8. PubMed ID: 7192139 [TBL] [Abstract][Full Text] [Related]
4. Characterization of a new potent heparin. 6th communication: The comparison of the anticoagulant effect of the sodium and calcium salts of a new potent heparin after s.c. injection in beagle dogs. Bhargava AS; Schöbel C; Günzel P Arzneimittelforschung; 1981; 31(1):79-82. PubMed ID: 7194097 [TBL] [Abstract][Full Text] [Related]
5. The monitoring of heparin administration by screening tests in experimental dogs. Mischke R; Jacobs C Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088 [TBL] [Abstract][Full Text] [Related]
6. Chemorheological studies of the effect of heparin on the course of coagulation. Overholser KA; Baysinger CB; Harris TR; Deveau T Thromb Haemost; 1976 Apr; 35(2):447-59. PubMed ID: 989642 [TBL] [Abstract][Full Text] [Related]
7. SSR182289A, a novel, orally active thrombin inhibitor: in vitro profile and ex vivo anticoagulant activity. Berry CN; Lassalle G; Lunven C; Altenburger JM; Guilbert F; Lalé A; Hérault JP; Lecoffre C; Pfersdorff C; Herbert JM; O'Connor SE J Pharmacol Exp Ther; 2002 Dec; 303(3):1189-98. PubMed ID: 12438543 [TBL] [Abstract][Full Text] [Related]
8. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate. Wang ZM; Li L; Li B; Guo SY Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476 [TBL] [Abstract][Full Text] [Related]
9. A dose-response study in animals to evaluate the anticoagulant effect of the stage 2 unfractionated heparin USP monograph change. Honchel R; Carraway J; Gopee N; Callicott R; Chen J; Patton R; Xu Q; Zalkkar J; Laniyonu A; Krefting I; Cato M; Robie-Suh K; Rieves R Regul Toxicol Pharmacol; 2011 Aug; 60(3):318-22. PubMed ID: 21549797 [TBL] [Abstract][Full Text] [Related]
10. Effect of gentamicin on heparin activity. Tyler LS; Rehder TL; Davis RB Am J Hosp Pharm; 1981 Apr; 38(4):537-40. PubMed ID: 7282683 [TBL] [Abstract][Full Text] [Related]
11. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs. Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide. Poggi A; Rossi C; Casella N; Bruno C; Sturiale L; Dossi C; Naggi A Semin Thromb Hemost; 2002 Aug; 28(4):383-92. PubMed ID: 12244486 [TBL] [Abstract][Full Text] [Related]
13. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants. Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547 [TBL] [Abstract][Full Text] [Related]
14. Fucosylated chondroitin sulfate as a new oral antithrombotic agent. Fonseca RJ; Mourão PA Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379 [TBL] [Abstract][Full Text] [Related]
15. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin. Bhargava AS; Heinick J; Günzel P Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289 [TBL] [Abstract][Full Text] [Related]
16. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina. Klootwijk P; Lenderink T; Meij S; Boersma H; Melkert R; Umans VA; Stibbe J; Müller EJ; Poortermans KJ; Deckers JW; Simoons ML Eur Heart J; 1999 Aug; 20(15):1101-11. PubMed ID: 10413640 [TBL] [Abstract][Full Text] [Related]
17. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research. Wilkerson RD; Conran PB; Greene SL Lab Anim Sci; 1984 Feb; 34(1):62-5. PubMed ID: 6716959 [TBL] [Abstract][Full Text] [Related]
18. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats. Hérault JP; Bernat A; Gaich C; Herbert M Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483 [TBL] [Abstract][Full Text] [Related]
19. A new route of heparin administration--the lung. Kavanagh LW; Jaques LB Arzneimittelforschung; 1976; 26(3):389-92. PubMed ID: 989334 [TBL] [Abstract][Full Text] [Related]
20. Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog. Johnstone IB; Martin CA Can J Vet Res; 2000 Apr; 64(2):117-22. PubMed ID: 10805251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]